Related Experiment Videos
Agranulocytosis associated with enalapril
DICP : the Annals of Pharmacotherapy
|May 1, 1991
Summary
Enalapril, an angiotensin-converting enzyme inhibitor, may cause agranulocytosis, a serious condition. This case highlights the potential risk even after prolonged use, emphasizing careful patient monitoring for adverse drug reactions.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Agranulocytosis is a rare but severe adverse drug reaction characterized by a significant reduction in neutrophils.
- Angiotensin-converting enzyme (ACE) inhibitors, such as captopril, have been linked to agranulocytosis in previous reports.
- Verapamil, a calcium channel blocker, has not been previously associated with agranulocytosis.